Infusion Therapy in Manhattan and NYC

Infusion therapy is a medically supervised treatment approach that delivers medication through an IV or infusion-based system. In pain and inflammatory care, infusions may be used for different purposes depending on the diagnosis. Some may be considered for selected chronic pain, neuropathic pain, CRPS, or treatment-resistant pain patterns. Others, such as biologic infusions, may be used for autoimmune or inflammatory conditions. At MPM, infusion therapy is not treated as a wellness IV service or a universal pain treatment.

Infusions used in chronic pain care may include ketamine-based therapy, lidocaine-based infusions, or other medically supervised protocols depending on the condition and patient safety profile. These treatments are not interchangeable. Ketamine may be considered for selected complex or treatment-resistant pain patterns, while lidocaine-based approaches may be considered in certain neuropathic pain contexts. MPM evaluates diagnosis, prior treatment history, medications, cardiovascular and neurologic risk, mental health history, and monitoring needs before determining whether an infusion may be appropriate.

Infusions may help selected neuropathic pain patients, but they are not appropriate for every nerve pain condition. Neuropathic pain can come from small fiber neuropathy, CRPS, nerve injury, spine-related nerve irritation, autoimmune disease, metabolic conditions, or other neurological disorders. Some infusion approaches, such as lidocaine or ketamine-based treatment, have been studied for certain neuropathic pain patterns, but response varies and long-term benefit is not guaranteed. MPM evaluates the diagnosis and safety profile before considering IV pain treatment.

Infusion therapy may be considered for selected patients with complex regional pain syndrome, especially when pain remains severe despite standard care. Ketamine-based infusions have been studied in CRPS and other refractory pain conditions, but results vary and treatment requires careful safety screening and monitoring. Infusions do not cure CRPS and should not replace rehabilitation, medication management, pain psychology, functional restoration, or other coordinated care. MPM evaluates whether infusion therapy fits the patient’s condition, risks, goals, and broader treatment plan.

Infusions may help selected autoimmune or inflammatory conditions when the treatment is directed at the underlying immune or inflammatory process. Biologic infusions may be used in conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis-related disease, or other inflammatory conditions when clinically appropriate. These treatments require careful medical oversight, infection screening, medication review, lab monitoring, and specialist coordination. Infusions do not replace diagnosis, rheumatology care, or broader autoimmune disease management.

Biologic infusions are immune-directed medications delivered by IV for certain inflammatory or autoimmune conditions. They are designed to target specific parts of the immune system involved in inflammation. Depending on the diagnosis, biologics may be used for conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, or other immune-mediated diseases. They are not general pain medications. Biologic infusion therapy requires medical supervision, infection risk review, monitoring, and coordination with the clinicians managing the inflammatory condition.

Biologic infusions and pain infusions have different goals. Biologic infusions are typically used to treat autoimmune or inflammatory disease activity by targeting immune pathways. Pain-modulating infusions, such as ketamine or lidocaine-based approaches, may be considered for selected neuropathic, CRPS, or treatment-resistant pain patterns. The risks, monitoring, dosing, and follow-up are different. MPM evaluates which category, if any, fits the patient’s diagnosis, medical history, treatment goals, and safety profile.

Ketamine therapy and lidocaine and ketamine infusions may involve different medications, protocols, monitoring needs, and treatment goals. Ketamine can affect pain signaling and may also cause sedation, dissociation, mood effects, nausea, or blood pressure and heart rate changes. Lidocaine-based infusions require careful cardiac and neurologic safety consideration. These treatments are not interchangeable. MPM determines whether either approach may be appropriate based on diagnosis, medical history, medications, risk factors, prior treatment response, and monitoring needs.

MPM begins with diagnosis. The team reviews the patient’s pain condition, inflammatory or autoimmune history, prior treatments, medications, labs when relevant, medical risks, mental health history, cardiovascular and neurologic safety factors, infection risk, and care goals. The question is not whether an infusion is available, but whether a specific infusion type matches the clinical problem and can be delivered safely. MPM may also coordinate with rheumatology, neurology, oncology, primary care, or other clinicians when needed.

Infusion length varies depending on the medication, protocol, monitoring requirements, and patient response. Some infusions may require preparation time, vital sign monitoring, observation during treatment, and post-infusion monitoring before the patient leaves. Other infusions may require lab review or specialist coordination before scheduling. MPM reviews the expected visit length, preparation instructions, and post-infusion requirements based on the specific infusion type being considered.

Infusions can be safe for selected patients when they are medically indicated, properly monitored, and matched to the patient’s health profile. They are not risk-free. Risks may include infusion reactions, allergic reactions, infection risk, blood pressure or heart rate changes, sedation, dizziness, nausea, dissociation or mood effects with ketamine, cardiac or neurologic risks with lidocaine, immune suppression with biologics, medication interactions, and condition-specific side effects. MPM reviews risks, monitoring needs, and alternatives before recommending infusion therapy.

Monitoring depends on the type of infusion. Some patients may need vital sign monitoring, medication review, lab monitoring, infection screening, cardiac or neurologic safety review, post-infusion observation, or coordination with another specialist. Ketamine, lidocaine, and biologic infusions each have different monitoring needs. MPM determines the appropriate safety plan before treatment and may recommend additional clearance or testing if the patient’s medical history raises concern.

Yes, infusion therapy may be combined with other treatments when clinically appropriate. Depending on the diagnosis, this may include medication management, physical rehabilitation, interventional procedures, biologics, pain psychology, headache care, rheumatology care, neurology care, or coordinated specialist treatment. Infusions are rarely the entire care plan. MPM uses them selectively within a broader diagnosis-first approach so treatment remains connected to the patient’s condition, safety profile, and functional goals.

Infusion therapy may need to be avoided or delayed when the diagnosis is unclear, the safety risks outweigh potential benefit, or another evaluation is needed first. Concerns may include unstable medical conditions, infection, medication interactions, uncontrolled blood pressure, certain cardiac or neurologic risks, severe psychiatric instability, immune suppression concerns, pregnancy-related considerations, or condition-specific contraindications. Patients should seek urgent care for trouble breathing, chest pain, severe allergic reaction, fainting, severe confusion, severe sedation, new neurological deficits, fever, signs of infection, severe headache, severe abdominal or pelvic pain, bowel or bladder dysfunction, rapidly worsening weakness, or rapidly worsening symptoms.